As neurocognitive impairment consists of a core domain of the clinical symptoms that tumor patients show,13,14 one would assume that IDH1 wild-type HGG would induce more severe neurocognitive deficits compared to their IDH1 mutant-type counterparts. This evidence concerns the gene IDH1 and neoplasm.